P. Goodman

发表

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

J. Crowley, I. Thompson, D. Pauler, 2004, The New England journal of medicine.

A Meta-Analysis Identifies New Loci Associated with Body Mass index in Individuals of African Ancestry

Xiaofeng Zhu, Olufunmilayo I. Olopade, Alex P. Reiner, 2013, Nature Genetics.

A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer

Peter Kraft, Jenny Donovan, Anssi Auvinen, 2014, Nature Genetics.

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

P. Goodman, E. Crawford, M. A. Davis, 1989, The New England journal of medicine.

Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, M. Lucia, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

K. D. Sørensen, H. Ostrer, T. Sellers, 2018, Nature Genetics.

Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, M. Lucia, 2015, The Prostate.

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.

T R Fleming, T. Fleming, P. Goodman, 1990, The New England journal of medicine.

Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group.

D Machin, J W Hand, S B Field, 1996, International journal of radiation oncology, biology, physics.

Discovery of common and rare genetic risk variants for colorectal cancer

Mathieu Lemire, Steven Gallinger, Michael Wainberg, 2018, Nature Genetics.

Vitamin E and the Risk of Prostate Cancer The Selenium and Vitamin E Cancer Prevention Trial ( SELECT )

J. Crowley, J. Chin, I. Thompson, 2011 .

Vitamin E supplementation increased risk for prostate cancer in healthy men at a median of 7 years

I. Thompson, P. Goodman, C. Tangen, 2012 .

Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium

Yu-Han H. Hsu, Sanjay R. Patel, J. Witte, 2017, PLoS genetics.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

Nawaid Usmani, Suzanne Chambers, Martin Eklund, 2018, Nature Communications.

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.

Ian M Thompson, J. Crowley, I. Thompson, 2005, JAMA.

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Ziding Feng, Ian M Thompson, I. Thompson, 2006, Journal of the National Cancer Institute.

Identifying novel susceptibility genes for colorectal cancer risk from a transcriptome-wide association study of 125,478 subjects.

Stephanie A. Bien, Xiaolong Wang, G. Abecasis, 2020, Gastroenterology.

Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, M. Lucia, 2021, Nutrition and cancer.

Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

R. Hoover, A. Tjønneland, G. Giles, 2015, The American journal of clinical nutrition.

Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT

P. Kantoff, I. Thompson, P. Goodman, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, M. Lucia, 2016, The Prostate.

Methodological Considerations in Estimation of Phenotype Heritability Using Genome-Wide SNP Data, Illustrated by an Analysis of the Heritability of Height in a Large Sample of African Ancestry Adults

Gary K. Chen, M. C. Leske, J. Witte, 2015, PloS one.

Prostate Cancer Susceptibility in Men of African Ancestry at 8q24.

Dennis J. Hazelett, M. C. Leske, J. Witte, 2016, Journal of the National Cancer Institute.

Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.

P. Goodman, C. Erlichman, J. Thiessen, 1993, Cancer research.

Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia

N. Malats, D. Silverman, N. Rothman, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Adenocarcinoma of the rectum treated by radical external radiation therapy.

P. Goodman, C. Catton, B. O'Sullivan, 1995, International journal of radiation oncology, biology, physics.

Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

I. Thompson, P. Goodman, A. Kristal, 2008, American journal of epidemiology.

Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

I. Thompson, P. Goodman, A. Kristal, 2007, The Journal of urology.

Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation

Henry W. Long, M. C. Leske, J. Witte, 2016, Nature Communications.

A Transcriptome-Wide Association Study (TWAS) Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer.

Geoffrey S. Tobias, Ashley A. Jermusyk, Jianxin Shi, 2020, Journal of the National Cancer Institute.

A Functional Variant in NKX3.1 Associated with Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

P. Goodman, C. Tangen, E. Klein, 2014, Cancer Prevention Research.

Estimated impact of the Prostate Cancer Prevention Trial on population mortality

J. Crowley, M. Leblanc, I. Thompson, 2005, Cancer.

Leuprolide With and Without Flutamide in Advanced Prostate Cancer

P. Goodman, E. Crawford, M. A. Davis, 1990, Cancer.

A phase II multi‐institutional trial of low‐dose N‐(phosphonacetyl)‐L‐aspartate and high‐dose 5‐fluorouracil as a short‐term infusion in the treatment of adenocarcinoma of the pancreas. A southwest oncology group study

T. Fleming, P. Goodman, J. Macdonald, 1991, Cancer.

Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk

Manal M. Hassan, N. Malats, D. Silverman, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Moving a randomized clinical trial into an observational cohort

J. Crowley, P. Goodman, C. Tangen, 2013, Clinical trials.

Long-Term Effects of Finasteride on Prostate Cancer Mortality.

I. Thompson, P. Goodman, C. Tangen, 2019, The New England journal of medicine.

SELECT: the selenium and vitamin E cancer prevention trial.

I. Thompson, P. Goodman, S. Lippman, 2003, Urologic oncology.

Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status

M. Kogevinas, A. Wolk, Jong Y. Park, 2022, Cancers.

Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologie studies Elizabeth A. PlatzSiobhan SutcliffeAngelo M. De Marzo • Charles G. DrakeNader RifaiAnn W. HsingAshraful Hoque •

P. Goodman, A. Kristal, M. Neuhouser, 2010 .

Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies

P. Goodman, A. Kristal, C. Drake, 2010, Cancer Causes & Control.

Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial

I. Thompson, P. Goodman, C. Tangen, 2016, The Prostate.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

M. Kattan, I. Thompson, P. Goodman, 2007, Journal of the National Cancer Institute.

Genetically predicted circulating concentrations of micronutrients and risk of colorectal cancer among individuals of European descent: a Mendelian randomization study.

C. Ulrich, H. Brenner, J. Chang-Claude, 2021, The American journal of clinical nutrition.

Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, E. Platz, 2014, Cancer Causes & Control.

Human Papillomavirus Types 16, 18, and 31 Serostatus and Prostate Cancer Risk in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, E. Platz, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Null Results in Brief Cancer Epidemiology , Biomarkers & Prevention Human Papillomavirus Types 16 , 18 , and 31 Serostatus and Prostate Cancer Risk in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, E. Platz, 2010 .

Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials.

J. Crowley, I. Thompson, P. Goodman, 2004, The Journal of urology.

Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

J. Chin, I. Thompson, P. Goodman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

J. Chin, I. Thompson, P. Goodman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, M. Lucia, 2020, The Prostate.

The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate‐specific antigen and biopsy outcome

I. Thompson, P. Goodman, C. Tangen, 2013, Cancer.

Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Michael M Lieber, J Michael Gaziano, Ian M Thompson, 2005, Journal of the National Cancer Institute.

R. Glynn, I. Thompson, P. Goodman, 2020, Acta ophthalmologica.

Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress.

P. Goodman, L. Minasian, S. Lippman, 2016, Free radical biology & medicine.

J. Crowley, R. Glynn, I. Thompson, 2015, JAMA ophthalmology.

Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

P. Brown, I. Thompson, P. Goodman, 2014, Cancer Prevention Research.

Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

J. Crowley, M. Spitz, J. Stanford, 2004, Cancer Causes & Control.

19 Utility of the enrollment period in the Prostate Cancer Prevention Trial (PCPT)

J. Crowley, I. Thompson, P. Goodman, 1997 .

The influence of finasteride on the development of prostate cancer.

Michael M Lieber, Ian M Thompson, Scott M Lippman, 2003, The New England journal of medicine.

Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2018, Carcinogenesis.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2017, The Prostate.

Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2017, Nutrients.

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2016, Cancer.

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2015, Cancer Causes & Control.

Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml−1, normal DRE and negative for prostate cancer

I. Thompson, P. Goodman, C. Tangen, 2015, Prostate Cancer and Prostatic Disease.

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.

I. Thompson, P. Goodman, C. Tangen, 2015, Urology.

Statin drug use is not associated with prostate cancer risk in men who are regularly screened.

I. Thompson, P. Goodman, C. Tangen, 2014, The Journal of urology.

Survival in the prostate cancer prevention trial.

I. Thompson, P. Goodman, C. Tangen, 2013, The New England journal of medicine.

Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride

I. Thompson, P. Goodman, C. Tangen, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study

I. Thompson, P. Goodman, C. Tangen, 2011, Cancer Causes & Control.

Serum Oxidized Protein and Prostate Cancer Risk within the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2010, Cancer Prevention Research.

Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial

P. Goodman, C. Tangen, 2009 .

Finasteride, prostate cancer, and weight gain: Evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment

I. Thompson, P. Goodman, C. Tangen, 2008, The Prostate.

Extraction of DNA from serum for high-throughput genotyping: findings from pilot studies within the Prostate Cancer Prevention Trial.

P. Goodman, Xifeng Wu, J. Conroy, 2008, Urology.

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

I. Thompson, P. Goodman, C. Tangen, 2006, Journal of the National Cancer Institute.

The prostate cancer prevention trial: design, biases and interpretation of study results.

J. Crowley, I. Thompson, P. Goodman, 2006, The Journal of urology.

A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.

Jack A. Taylor, T. Sellers, J. Carpten, 2020, European urology.

Implementation of the Prostate Cancer Prevention Trial (PCPT).

J. Crowley, I. Thompson, P. Goodman, 2004, Controlled clinical trials.

Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial

P. Goodman, E. Platz, A. D. De Marzo, 2009, International journal of cancer.

Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial.

I. Thompson, P. Goodman, M. Neuhouser, 2021, Endocrine-related cancer.

The Prostate Cancer Prevention Trial: Current status and lessons learned.

I. Thompson, P. Goodman, C. Coltman, 2001, Urology.

Hepcidin-regulating Iron-metabolism Genes and Pancreatic Ductal Adenocarcinoma: A Pathway Analysis of Genome-wide Association Studies

Debra T. Silverman, Manal M. Hassan, M. Schulze, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Effect Of Vitamin E And Selenium On Rate Of Decline In FEV1: The Respiratory Ancillary Study To The Selenium And Vitamin E Cancer Prevention Trial (SELECT)

J. Crowley, P. Goodman, C. Tangen, 2011, ATS 2011.

Pazopanib versus Sunitinib in Renal Cancer

I. Thompson, P. Goodman, 2013 .

Results of a policy of surveillance in stage I testicular seminoma.

P. Goodman, C. Catton, P. Warde, 1993, International journal of radiation oncology, biology, physics.

A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry.

Jack A. Taylor, T. Sellers, J. Carpten, 2022, European urology.

A randomized trial of two schedules of trimetrexate versus 5‐fluorouracil in advanced colorectal cancer: a Southwest Oncology Group Study

T. Fleming, P. Goodman, J. Macdonald, 1995, Anti-cancer drugs.

High incidence of coagulopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers

T. Fleming, P. Goodman, E. Hersh, 1992 .

High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers.

T. Fleming, P. Goodman, E. Hersh, 1992, Anti-cancer drugs.

Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, E. Platz, 2012, Cancer Causes & Control.

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.

P. Goodman, B. Redman, E. Crawford, 1990, Journal of the National Cancer Institute.

Erectile Dysfunction and Incidence of Cardiovascular Disease—Reply

I. Thompson, P. Goodman, C. Tangen, 2006 .

470: Comparison of the Operating Characteristics of PSA for Prostate Cancer Detection for Finasteride and Placebo in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2006 .

1664: Pathological Assessment of High Grade Tumors in the Prostate Cancer Prevention Trial (PCPT)

I. Thompson, P. Goodman, C. Tangen, 2005 .

Cumulative Burden of Colorectal Cancer-Associated Genetic Variants is More Strongly Associated With Early-onset vs Late-onset Cancer.

Stephanie A. Bien, Elizabeth L. Barry, Aung Ko Win, 2019, Gastroenterology.

Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, E. Platz, 2015, Cancer Causes & Control.

Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI.

I. Thompson, P. Goodman, C. Tangen, 2019, Cancer epidemiology.

Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.

I. Thompson, P. Goodman, C. Tangen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors Associated with Adherence to an End-of-Study Biopsy: Lessons from the Prostate Cancer Prevention Trial (SWOG-Coordinated Intergroup Study S9217)

I. Thompson, P. Goodman, C. Tangen, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, H. Parnes, 2009, Cancer Epidemiology, Biomarkers & Prevention.

Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach

I. Thompson, P. Goodman, C. Tangen, 2008, Cancer Prevention Research.

Erectile dysfunction and subsequent cardiovascular disease.

I. Thompson, P. Goodman, C. Tangen, 2005, JAMA.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts

I. Thompson, P. Goodman, C. Tangen, 2017, Cancer Epidemiology, Biomarkers & Prevention.

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

J. Crowley, I. Thompson, P. Goodman, 2009, JAMA.

Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.

Ian M Thompson, Lori M Minasian, Scott M Lippman, 2014, Journal of the National Cancer Institute.

Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.

Jason D. Wright, I. Thompson, P. Goodman, 2016, Journal of the National Cancer Institute.

Treatment of stages B3 and C seminoma with chemotherapy followed by irradiation therapy. Southwest Oncology Group Study.

P. Goodman, E. Crawford, K. Khan, 1992, Urology.

Stage I testicular seminoma: results of adjuvant irradiation and surveillance.

P. Goodman, C. Catton, P. Warde, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions.

Henry W. Long, Dennis J. Hazelett, M. C. Leske, 2015, Human molecular genetics.

American Journal of Epidemiology Original Contribution Diet, Supplement Use, and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, A. Kristal, 2022 .

Associations between Genetically Predicted Blood Protein Biomarkers and Pancreatic Cancer Risk

N. Malats, C. Kooperberg, G. Giles, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3

Manal M. Hassan, E. Riboli, N. Malats, 2021, Cancer Research.

Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer

Peter Kraft, Krzysztof Jamroziak, Pavel Soucek, 2018, Nature Communications.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature Genetics.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature genetics.

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

I. Thompson, P. Goodman, C. Tangen, 2014, Journal of the National Cancer Institute.

Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk

Manal M. Hassan, Peter T Campbell, Jianxin Shi, 2020, Cancer Research.

Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21

Alison P. Klein, Nan Hu, Peter Kraft, 2016, Oncotarget.

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer

Yusuke Nakamura, Nan Hu, Peter Kraft, 2014, Nature Genetics.

Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

P. Goodman, H. Parnes, A. Kristal, 2010, Cancer Prevention Research.

Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase

Ruth Etzioni, I. Thompson, P. Goodman, 2006, Cancer.

Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2015, The Prostate.

Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, S. Lippman, 2006, Cancer Epidemiology Biomarkers & Prevention.

Genetic architectures of proximal and distal colorectal cancer are partly distinct

Richard T. Barfield, Stephanie A. Bien, G. Abecasis, 2020, Gut.

Incorporating Genetic Determinants of Prostate-Specific Antigen Levels Improves Prostate Cancer Screening

S. Chanock, P. Goodman, D. Conti, 2022, medRxiv.

Generalizability of established prostate cancer risk variants in men of African ancestry

M. C. Leske, J. Witte, J. Carpten, 2015, International journal of cancer.

A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR): 97

P. Goodman, M. Moore, C. Erlichman, 1994 .

Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2015, PloS one.

Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.

P. Goodman, A. Cruz, V. Vaitkevicius, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk

Geoffrey S. Tobias, Manal M. Hassan, N. Malats, 2015, PloS one.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

J. Witte, M. Lieber, G. Colditz, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.

Jacob M. Keaton, Jack A. Taylor, J. Witte, 2023, European urology.

A Pooled Analysis of 15 Prospective Cohort Studies on the Association between Fruit, Vegetable, and Mature Bean Consumption and Risk of Prostate Cancer

P. A. van den Brandt, E. Riboli, M. McCullough, 2017, Cancer Epidemiology, Biomarkers & Prevention.

Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial.

I. Thompson, P. Goodman, A. Kristal, 2011, American journal of epidemiology.

Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2020, Cancer Prevention Research.

Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium Trial (PREADViSE)

J. Crowley, P. Goodman, F. Schmitt, 2017, JAMA neurology.

Alcohol consumption, finasteride, and prostate cancer risk

I. Thompson, P. Goodman, C. Tangen, 2009, Cancer.

Meta‐analysis of 16 studies of the association of alcohol with colorectal cancer

D. English, H. Brenner, J. Chang-Claude, 2020, International journal of cancer.

Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial

Jun O. Liu, I. Thompson, P. Goodman, 2020, Cancer Prevention Research.

Serum 25-Hydroxyvitamin D Concentrations and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

P. Goodman, C. Tangen, A. Kristal, 2014, Cancer Epidemiology, Biomarkers & Prevention.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

J. Witte, G. Colditz, A. Olshan, 2020, Blood advances.

SELECT: THE NEXT PROSTATE CANCER PREVENTION TRIAL

I. Thompson, P. Goodman, S. Lippman, 2001 .

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

I. Thompson, P. Goodman, C. Tangen, 2014, Urology.

Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT.

I. Thompson, P. Goodman, C. Tangen, 2012, The Journal of urology.

The Selenium and Vitamin E Cancer Prevention Trial

I. Thompson, P. Goodman, S. Lippman, 2003, World Journal of Urology.

SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design

I. Thompson, P. Goodman, S. Lippman, 2000, Prostate Cancer and Prostatic Diseases.

Phase II evaluation of amonafide in renal cell carcinoma

P. Goodman, C. Higano, E. Crawford, 1991, Investigational New Drugs.

A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study.

T. Fleming, P. Goodman, E. Hersh, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.

T. Fleming, P. Goodman, E. Hersh, 1990, Journal of biological response modifiers.

Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience

I. Thompson, P. Goodman, C. Tangen, 2010, Cancer Prevention Research.

The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.

I. Thompson, P. Goodman, C. Tangen, 2008, The Journal of urology.

Chemoprevention of prostate cancer.

I. Thompson, P. Goodman, C. Tangen, 1994, The Journal of urology.

Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry.

Scott M. Williams, Yu-Han H. Hsu, Nicholette D. Palmer, 2021, American journal of human genetics.

Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

Jack A. Taylor, O. Andreassen, A. Dale, 2021, Prostate Cancer and Prostatic Diseases.

African‐specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

Jack A. Taylor, O. Andreassen, R. Eeles, 2020, medRxiv.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

K. D. Sørensen, Ali Amin Al Olama, H. Ostrer, 2019, Nature Genetics.

A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma. A Southwest Oncology Group study.

P. Goodman, C. Presant, D. V. Von Hoff, 1990, European journal of cancer.

Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention

D. Alberts, E. Jacobs, I. Thompson, 2016, Cancer Prevention Research.

Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2018, Journal of the National Cancer Institute.

SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial.

I. Thompson, P. Goodman, S. Lippman, 2001, The Journal of urology.

Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial

J. Crowley, P. Goodman, C. Tangen, 2016, Trials.

A randomized controlled Alzheimer’s disease prevention trial’s evolution into an exposure trial: The preadvise trial

J. Crowley, P. Goodman, F. Schmitt, 2012, The journal of nutrition, health & aging.

Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies

E. Metter, P. A. van den Brandt, B. Henderson, 2016, Journal of the National Cancer Institute.

Circulating sex hormones in relation to anthropometric, sociodemographic and behavioural factors in an international dataset of 12,300 men

A. Whittemore, L. Ferrucci, E. Metter, 2017, PloS one.

Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

I. Thompson, P. Goodman, C. Tangen, 2011, Carcinogenesis.

Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer.

Geoffrey S. Tobias, N. Malats, D. Silverman, 2018, Journal of the National Cancer Institute.

Associations Between Polymorphisms in Genes Related to Oxidative Stress and DNA Repair, Interactions With Serum Antioxidants, and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2022, Frontiers in Oncology.

A randomized controlled trial of vitamin E and selenium on rate of decline in lung function

J. Crowley, P. Goodman, C. Tangen, 2015, Respiratory Research.

Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

M. Scott Lucia, William D. Figg, Alan Kristal, 2013, Cancer Prevention Research.

Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial

I. Thompson, P. Goodman, C. Tangen, 2008, The Prostate.

Rapid Review Alert July 11 , 2013 ADVANCES In EPA & DHA Research

I. Thompson, P. Goodman, C. Tangen, 2013 .

Correction: Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk

Geoffrey S. Tobias, N. Malats, S. Chanock, 2015, PloS one.

Long-term survival of participants in the prostate cancer prevention trial.

Ian M Thompson, Lori M Minasian, I. Thompson, 2013, The New England journal of medicine.

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.

Ruth Etzioni, I. Thompson, P. Goodman, 2005, The Journal of urology.

Modeling the Effect of a Preventive Intervention on the Natural History of Cancer: Application to the Prostate Cancer Prevention Trial

Paul F. Pinsky, Nadia Howlader, Ruth Etzioni, 2006 .

Adding genetic risk score to family history identifies twice as many high‐risk men for prostate cancer: Results from the prostate cancer prevention trial

I. Thompson, P. Goodman, C. Tangen, 2016, The Prostate.

Dietary Supplement Use in the Prostate Cancer Prevention Trial: Implications for Prevention Trials

I. Thompson, P. Goodman, A. Kristal, 2001, Nutrition and cancer.

Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study

P. Goodman, T. Fleming, J. Macdonald, 1993, Anti-cancer drugs.

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

I. Thompson, P. Goodman, C. Tangen, 2010, The Journal of urology.

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Lori J Sokoll, Javier Hernandez, Donna P Ankerst, 2014, Urology.

Pathologic Characteristics of Cancers Detected in the Prostate Cancer Prevention Trial: Implications for Prostate Cancer Detection and Chemoprevention

I. Thompson, P. Goodman, M. Lucia, 2008, Cancer Prevention Research.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

I. Thompson, P. Goodman, C. Tangen, 2007, Journal of Clinical Oncology.

Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.

I. Thompson, P. Goodman, C. Tangen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insulin-LikeGrowth Factor-I, Insulin-LikeGrowth FactorBinding Protein-3 andRiskof Benign Prostate Hyperplasia in the ProstateCancer PreventionTrial

I. Thompson, P. Goodman, C. Tangen, 2008 .

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2016, Cancer Causes & Control.

Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

I. Thompson, P. Goodman, A. Kristal, 2008, American journal of epidemiology.

Radiation treatment of cervical lymph node metastases from an unknown primary: an analysis of outcome by treatment volume and other prognostic factors.

P. Goodman, P. Warde, B. O'Sullivan, 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Biomarker-based methods for determining noncompliance in a prevention trial.

J. Crowley, I. Thompson, D. Pauler, 2002, Controlled clinical trials.

Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium

M. McCullough, C. Haiman, P. Goodman, 2018, Gut.

Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies

R. Sinha, P. A. van den Brandt, D. Spiegelman, 2016, International journal of cancer.

A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial.

J. Crowley, P. Goodman, F. Schmitt, 2012, The journal of nutrition, health & aging.

The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.

M. Leblanc, I. Thompson, P. Goodman, 2017, Cancer epidemiology.

Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score.

I. Thompson, P. Goodman, C. Tangen, 2013, Urology.

The Prostate Cancer Prevention Trial: design, status, and promise

I. Thompson, P. Goodman, C. Tangen, 2003, World Journal of Urology.

Chronic In fl ammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

I. Thompson, P. Goodman, C. Tangen, 2014 .

Genetically adjusted PSA levels for prostate cancer screening

J. Witte, S. Chanock, P. Goodman, 2023, Nature Medicine.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

K. D. Sørensen, Ali Amin Al Olama, H. Ostrer, 2019, Nature Genetics.

The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.

Ziding Feng, Daniel W Chan, Donna P Ankerst, 2013, The Journal of urology.

Is there a role for body mass index in the assessment of prostate cancer risk on biopsy?

I. Thompson, P. Goodman, E. Klein, 2014, The Journal of urology.

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

I. Thompson, P. Goodman, C. Tangen, 2012, American journal of epidemiology.

Discovery of common and rare genetic risk variants for colorectal cancer

Stephanie A. Bien, Aung Ko Win, Sarah C. Nelson, 2018, Nature Genetics.

A Southwest Oncology Group phase H study (8504)

P. Goodman, E. Crawford, R. Natale, 1990 .

Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride

M. Scott Lucia, Michael LeBlanc, James Y. Dai, 2018, Cancer Prevention Research.

Circadian genes and risk of prostate cancer in the prostate cancer prevention trial

Summer S. Han, I. Thompson, P. Goodman, 2018, Molecular carcinogenesis.

A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer

M. Martí-Renom, E. López de Maturana, L. Alonso, 2020, bioRxiv.

Selenium and Prostate Cancer : Analysis of Individual Participant Data From Fifteen Prospective Studies

B. Henderson, P. Goodman, M. Stampfer, 2016 .

Two Susceptibility Loci Identified for Prostate Cancer Aggressiveness

J. Witte, J. Carpten, H. Grönberg, 2015, Nature Communications.

Reduced Risk of Prostate Cancer With 5α-Reductase Inhibitors.

P. Goodman, C. Tangen, I. Thompson, 2018, Journal of the National Cancer Institute.

Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry

K. D. Sørensen, Ali Amin Al Olama, H. Ostrer, 2019, Nature Communications.

Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.

T. Wilt, P. Scardino, I. Thompson, 2014, Journal of the National Cancer Institute.

The influence of finasteride on the development of prostate cancer.

I. Thompson, P. Goodman, C. Tangen, 2003, The New England journal of medicine.

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.

I. Thompson, P. Goodman, C. Tangen, 2007, The Journal of urology.

Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

J. Crowley, M. Spitz, J. Stanford, 2004, Cancer Causes and Control.

The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer: 101

P. Goodman, M. Moore, C. Erlichman, 1994 .

Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

Tangen, P. Goodman, C. Tangen, 2014, Journal of the National Cancer Institute.

Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride

P. Goodman, C. Tangen, S. Lippman, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

M. Kattan, P. Goodman, C. Tangen, 2007, Journal of the National Cancer Institute.

Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score.

P. Goodman, C. Tangen, D. Ankerst, 2013, Urology.

Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention Trial

P. Goodman, C. Tangen, H. Parnes, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Generalizability of established prostate cancer risk variants in men of African ancestry

J. Witte, J. Carpten, S. Chanock, 2015, International journal of cancer.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

J. Crowley, D. Pauler, P. Goodman, 2004, The New England journal of medicine.

Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies.

Manal M. Hassan, D. Silverman, S. Chanock, 2021, The American journal of clinical nutrition.

Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction

P. Goodman, J. Long, S. K. Van Den Eeden, 2023, medRxiv.

Colorectal Adenomas in Participants of the SELECT Randomized Trial of Selenium and Vitamin E for Prostate Cancer Prevention

D. Alberts, E. Jacobs, P. Goodman, 2016, Cancer Prevention Research.

Chemoprevention of prostate cancer.

P. Goodman, C. Tangen, M. Lucia, 1994, The Journal of urology.

Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial

P. Goodman, E. Platz, A. D. De Marzo, 2009, International journal of cancer.

Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial

P. Goodman, H. Parnes, A. Kristal, 2009, Cancer Epidemiology, Biomarkers & Prevention.

American Journal of Epidemiology Original Contribution Serum Phospholipid Fatty Acids and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

P. Goodman, A. Kristal, D. Albanes, 2022 .

Abstract 3517: A germline variant at 8q24 contributes to familial clustering of prostate cancer in men of African ancestry

Jack A. Taylor, T. Sellers, J. Carpten, 2020, Epidemiology.

A Meta-Analysis Identifies New Loci Associated with Body Mass index in Individuals of African Ancestry

Gary K. Chen, Scott M. Williams, Nicholette D. Palmer, 2013, Nature Genetics.

Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer.

Geoffrey S. Tobias, N. Malats, D. Silverman, 2018, Journal of the National Cancer Institute.

Change in Plasma Alpha-Tocopherol Associations with Attenuated Pulmonary Function Decline and with CYP4F2 Missense Variation

P. Goodman, C. Tangen, A. Kristal, 2021, medRxiv.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts

P. Goodman, C. Tangen, M. Lucia, 2017, Cancer Epidemiology, Biomarkers & Prevention.

Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

K. D. Sørensen, Jacob M. Keaton, R. Mägi, 2023, Nature Genetics.